Immunic consensus stays bullish, analysts back IMUX shares
Published on 06/22/2026 at 21:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-22, 21:43.
Immunic Inc (US45256V1061) sits in the biotech segment on NASDAQ with a clearly positive analyst stance. Six Wall Street analysts currently rate the shares Strong Buy, according to a consensus snapshot published on June 22, 2026. Public.com consensus overview
What analysts are signaling
The consensus for Immunic is unambiguously bullish: 100 percent of the six analysts in the sample classify the stock as Strong Buy, with no Hold or Sell ratings reported. The implied average price target stands at 10.92 US dollars per share as of June 22, 2026. Analyst rating summary on Public.com
The same dataset underscores that these recommendations reflect recent research and market trend assessments in the biotechnology and pharmaceutical products space. Immunic therefore currently ranks among the more favorably viewed small-cap drug developers tracked on NASDAQ, compared with many peers carrying mixed Buy and Hold distributions. MarketBeat sector classification
Technical picture for IMUX on NASDAQ
On the technical side, Immunic shares most recently closed at 14.20 US dollars on NASDAQ on June 18, 2026, giving the company a market capitalization of roughly 193 million US dollars. This closing print places the stock inside a trading corridor defined by support at 11.46 dollars and resistance at 16.36 dollars. TradingKey technical analysis
TradingKey reports that Immunic currently has a price momentum score of 9.26 and ranks 39th out of 389 names in the Biotechnology & Medical Research industry in that framework. Based on a combination of moving averages from 5-day to 200-day periods, the same tool identifies six buy signals and no sell signal, with the overall daily technical signal marked as Buy. TradingKey moving-average signals
More news and background on the Immunic shares
All company disclosures, price data and previous reports on Immunic are collected on the dedicated topic page and via the company’s investor relations hub.
How Immunic aims to make money
Immunic focuses on developing oral therapies for chronic inflammatory and autoimmune diseases, especially in gastroenterology. Its pipeline includes vidofludimus calcium, an oral immunology drug candidate targeting conditions such as ulcerative colitis and Crohn’s disease, alongside other small-molecule programs in earlier stages. Company pipeline overview
Where the IMUX shares last traded
The Immunic shares (US45256V1061) last closed on NASDAQ at 14.20 US dollars on 2026-06-18 at 16:00 Eastern Time.
Key data on the Immunic shares
- Company: Immunic Inc
- ISIN: US45256V1061
- WKN: A2N9H3
- Ticker: IMUX
- Trading venue: NASDAQ
- Price (as of 2026-06-18, 16:00): 14.20 USD
- Market cap: 193.43 million USD (as of 2026-06-18)
- Sector / industry: Biotechnology / Pharmaceutical products
- Index membership: not included in major headline indices such as S&P 500 or NASDAQ-100
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. All data are based on sources believed to be reliable but cannot be guaranteed. Investors should conduct their own research and consider their individual financial situation.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
